Abstracts tagged "Disease Activity"

Abstract Number: 2494 • 2016 ACR/ARHP Annual Meeting
The Effect of Body Mass on DAS28 Response in Patients with Rheumatoid Arthritis Treated with Abatacept
J Fransen¹, L Tweehuysen², A den Broeder³, R Postema⁴, E Alemao⁵ and F van den Hoogen⁶, ¹Department of Rheumatolgy, Radboud UMC, Nijmegen, Netherlands, ²Sint Maartenskliniek Nijmegen, Nijmegen, Netherlands, ³Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ⁴Bristol-Myers Squibb, Uxbridge, United Kingdom, ⁵Bristol-Myers Squibb, Princeton, NJ, ⁶Rheumatology, Radboud UMC, Nijmegen, Netherlands
Background/Purpose: Abatacept is an effective biologic agent indicated for the treatment of RA.1 Recent studies have indicated that obesity and being overweight could reduce the…
Abstract Number: 2728 • 2016 ACR/ARHP Annual Meeting
Discontinuation of Biologic Therapy in Patients with Ankylosing Spondylitis—Data from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Philip J Mease¹, Désirée van der Heijde², Chitra Karki³, Mei Liu³, Renganayaki Pandurengan³, Yujin Park⁴ and Jeffrey D. Greenberg^3,5, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Corrona, LLC, Southborough, MA, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵New York University School of Medicine, New York, NY
Background/Purpose: Clinical trials have demonstrated the efficacy of biologic therapy in improving the clinical and patient-reported outcomes in patients with ankylosing spondylitis (AS); however, there…
Abstract Number: 2940 • 2016 ACR/ARHP Annual Meeting
Bechet’s Disease and Sleep Quality in Korean Patients
Chang-Nam Son¹, Ji Min Lee¹, Hye-Jin Jeong², Ji-Min Kim¹, Sang-Hyon Kim¹, Sung Soo Kim³ and Seung-Hyeon Bae⁴, ¹Division of Rheumatology, Department of Internal Medicine, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Korea, The Republic of, ²Division of Rheumatology, Department of Internal Medicine, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, South Korea, ³Division of Rheumatology, Department of Internal Medicine, Ulsan University School of Medicine, GangNeung Asan Hospital, Gangneung, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea
Background/Purpose: The purpose of this study was to find out the effects of sleep quality on Behcet’s disease in Korean population. We also investigated the…
Abstract Number: 450 • 2016 ACR/ARHP Annual Meeting
Coming Full Circle with the Omeract RA Flare Questionnaire (RA-FQ): Further Evaluation of the Properties, Meaningfulness, and Utility through Rasch Analysis and Feedback from RA Patients
Susan J. Bartlett^1,2, Skye Barbic³, Vivian P. Bykerk⁴, Bruno Fautrel⁵, Francis Guillemin⁶, A den Broeder⁷, R Alten⁸, Robin Christensen⁹, Ernest H. Choy¹⁰, Daniel E. Furst¹¹, Sarah Hewlett¹², Amye L. Leong¹³, Lyn March¹⁴, Thasia G Woodworth¹⁵, Clifton Bingham III¹⁶ and OMERACT Flare Group and Canadian Early Arthritis Cohort (CATCH) Investigators, ¹Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³University of British Columbia, Vancouver, BC, Canada, ⁴Divison of Rheumatology, Hospital for Special Surgery, New York, NY, ⁵Rheumatology, AP-HP Pitié-Salpêtrière Hospital / Pierre and Marie Curie University Paris 6 GRC-08 (EEMOIS), Paris, France, ⁶University of Lorraine, Nancy, France, ⁷Rheumatology, Maartenskliniek, Nijmegen, Netherlands, ⁸Schlosspark-Klinik University Medicine, Berlin, Germany, ⁹The Parker instutute, RC, Copenhagen, Denmark, ¹⁰Section of Rheumatology, Cardiff University, Cardiff, Great Britain, ¹¹University of California, Los Angeles, Los Angeles, CA, ¹²Academic Rheumatology, University of West of England, Bristol, United Kingdom, ¹³Spokesperson; Strategic Relations, BONE AND JOINT DECADE, Santa Barbara, CA, ¹⁴Department of Rheumatology, Northern Clinical School, Institute of Bone and Joint Research, Kolling Institute, University of Sydney & Department of Rheumatology, Royal North Shore Hospital, St Leonards, Sydney, Australia, ¹⁵Leading Edge Clinical Research, Stuart, FL, ¹⁶Johns Hopkins University, Baltimore, MD
Background/Purpose: OMERACT Filter 2.0 encourages use of robust methods to develop new measures. Instrument results also should be highly relevant, easily scored and interpreted, and…
Abstract Number: 637 • 2016 ACR/ARHP Annual Meeting
Biologic Initiation Patterns Among Rheumatoid Arthritis Patients in Moderate or High Disease Activity While Using Conventional Disease Modifying Anti-Rheumatic Drugs
Natalie Boytsov¹, George W. Reed², Leslie R Harrold^2,3, Xiang Zhang¹, Carol L Gaich¹, Cynthia J Larmore¹, Ying Shan², S Rebello⁴ and Andre B. Araujo¹, ¹Eli Lilly and Company, Indianapolis, IN, ²Corrona, LLC, Southborough, MA, ³UMass Medical School, Worcester, MA, ⁴Epidemiology, Corrona, Southborough, MA
Background/Purpose: The purpose of this study was to describe biologic initiation patterns over a 1-year follow-up period in rheumatoid arthritis (RA) patients with moderate…
Abstract Number: 954 • 2016 ACR/ARHP Annual Meeting
Effectiveness of Different Dosages of Retreatment of Rituximab in Combination with Leflunomide: Results from a Multicenter Randomized Placebo Controlled Investigator Initiated Clinical Trial in Active Rheumatoid Arthritis (Amara-Study
Frank Behrens¹, Tanja Rossmanith², Michaela Koehm³, Rieke Alten⁴, Martin Aringer⁵, GR Burmester⁶, Eugen Feist⁷, Klaus Krüger⁸, Ulf Müller-Ladner⁹, Andrea Rubbert-Roth¹⁰, Siegfried Wassenberg¹¹, Hans-Peter Tony¹², Herbert Kellner¹³, Marina Backhaus¹⁴ and Harald Burkhardt¹, ¹Division of Rheumatology and Fraunhofer IME-Project-Group Translational Medicine and Pharmacology, Goethe University, Frankfurt, Germany, ²Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine & Pharmacology TMP, Frankfurt, Germany, ³Division of Rheumatology and Fraunhofer IME-Project-Group Translational Medicine and Pharmacology, Goethe University, Frankfurt/Main, Germany, ⁴Schlosspark-Klinik University Medicine, Berlin, Germany, ⁵Abteilung für Rheumatologie, Dresden, Germany, ⁶Charité – University Medicine Berlin, Berlin, Germany, ⁷Charité-Universitätsmedizin Berlin, Berlin, Germany, ⁸Praxiszentrum St. Bonifatius, München, Germany, ⁹Justus-Liebig-University Giessen, Department of Internal Medicine and Rheumatology, Kerckhoff-Klinik, Bad Nauheim, Germany, Bad-Nauheim, Germany, ¹⁰Division Rheuamatology, University Köln, Köln, Germany, ¹¹Rheumazentrum, Ratingen, Germany, ¹²Rheumatology/Immunology, Medical Clinic II, University Clinic Wuerzburg, Würzburg, Germany, ¹³Rheumatology Patient Care, Munchen, Germany, ¹⁴Rheumatology, Park-Klinik Weissensee, Berlin, Germany
Background/Purpose: Use of biologicals such as Rituximab (RTX) in Rheumatoid Arthritis (RA) is effective and often only licensed in combination with Methotrexate (MTX). In cases…
Abstract Number: 1415 • 2016 ACR/ARHP Annual Meeting
Impact of the Clinical Disease Activity Index to Treat to Target Rheumatoid Arthritis in the Ambulatory Setting
Irene Lazarus¹, Salahuddin Kazi², Alok Dwivedi³, Christopher Dodoo⁴ and Kanchan Pema⁵, ¹Internal Medicine, Texas Tech University Health Science Center, El Paso, TX, ²Rheumatology, UT Southwestern Medical Center, Dallas, TX, ³Biomedical Sciences Division of Biostatistics and Epidemiology, Texas Tech University Health Sciences Center, El Paso, TX, ⁴Texas Tech University Health Sciences Center, El Paso, TX, ⁵Internal Medicine/Rheumatology, Texas Tech University Health Science Center, El Paso, TX
Background/Purpose: Since 2008 the Center for Medicare and Medicaid Services (CMS) has been in the process of changing patient care to quality-valued healthcare. In order…
Abstract Number: 1683 • 2016 ACR/ARHP Annual Meeting
Influence of Axial Involvement on Clinical Characteristics of Psoriatic Arthritis—Descriptive Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Philip J Mease¹, Chitra Karki², Mei Liu², Arthur Kavanaugh³, Renganayaki Pandurengan², Christopher T. Ritchlin⁴, Jacqueline B. Palmer⁵ and Jeffrey D. Greenberg^2,6, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Corrona, LLC, Southborough, MA, ³University of California San Diego, La Jolla, CA, ⁴Allergy, Immunology and Rheumatololgy Division, University of Rochester Medical Center, Rochester, NY, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶New York University School of Medicine, New York, NY
Background/Purpose: Although spinal involvement has been well studied in ankylosing spondylitis,1 very few studies in psoriatic arthritis (PsA) have characterized patients with axial involvement. The…
Abstract Number: 1995 • 2016 ACR/ARHP Annual Meeting
Smoking Is Associated with Unfavorable Flare/ Remission Pattern in Patients with Rheumatoid Arthritis
Shafay Raheel¹, Cynthia S. Crowson², Eric L. Matteson¹ and Elena Myasoedova¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic, Rochester, MN
Background/Purpose: Smoking is well recognized as a risk factor for rheumatoid arthritis (RA), and determinant of RA disease activity, severity, response to therapy, and possibly…
Abstract Number: 2495 • 2016 ACR/ARHP Annual Meeting
The Prevalence of Loss of Response to Treatment with a Tumor Necrosis Factor Inhibitor and/or Methotrexate in Patients with Rheumatoid Arthritis
Josef Smolen¹, Yihan Li², Iain Sainsbury², Stefan Florentinus², Kershnie Rambalee² and GR Burmester³, ¹Internal Medicine III, Div. of Rheumatology, Medical University of Vienna, Vienna, Austria, ²AbbVie Inc., North Chicago, IL, ³Charité – University Medicine Berlin, Berlin, Germany
Background/Purpose: Patients (pts) with rheumatoid arthritis (RA) who achieve disease control in response to treatment with a tumor necrosis factor inhibitor (TNFi) may lose that…
Abstract Number: 2736 • 2016 ACR/ARHP Annual Meeting
Do Validated Tools of Disease Activity in Ankylosing Spondylitis Measure Fibromyalgia Pain?
Marina N. Magrey¹, Sherilyn Diomampo² and Muhammad Asim Khan³, ¹Case Western Reserve University at MetroHealth Medical Center, Cleveland, OH, ²MetroHealth Medical Center, Cleveland, OH, ³Medicine/ Rheumatology, Case Western Reserve Univ, Cleveland, OH
Background/Purpose: Concomitant fibromyalgia syndrome (FMS) is a common problem in ankylosing spondylitis (AS) and its recognition is important for optimal management. BASDAI, a disease activity…
Abstract Number: 2965 • 2016 ACR/ARHP Annual Meeting
Late-Onset Relapse in Patients with Systemic Vasculitis
Rennie L. Rhee¹, Natasha Dehghan², Antoine G. Sreih³, David Cuthbertson⁴, Simon Carette⁵, Gary S. Hoffman⁶, Nader A. Khalidi⁷, Curry L. Koening⁸, Jeffrey Krischer⁹, Carol A. Langford¹⁰, Carol A. McAlear¹¹, Paul A. Monach¹², Larry W. Moreland¹³, Christian Pagnoux¹⁴, Philip Seo¹⁵, Ulrich Specks¹⁶, Steven R. Ytterberg¹⁷ and Peter A. Merkel¹⁸, ¹Rheumatology, University of Pennsylvania, Philadelphia, PA, ²University of British Columbia, Vancouver, BC, Canada, ³Rheumatology, The University of Pennsylvania, Philadelphia, PA, ⁴Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ⁵Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁶Rheumatology, Cleveland Clinic, Cleveland, OH, ⁷McMaster University, St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁸Rheumatology, University of Utah, Salt Lake City, UT, ⁹University of South Florida, Tampa, FL, ¹⁰Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ¹¹University of Pennsylvania, Philadelphia, PA, ¹²Rheumatology, Boston University School of Medicine, Boston, MA, ¹³Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹⁴Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹⁵Medicine, Johns Hopkins University, Baltimore, MD, ¹⁶Mayo Clinic, Rochester, MN, ¹⁷Rheumatology, Mayo Clinic, Rochester, MN, ¹⁸Division of Rheumatology, Univ of Pennsylvania; Perelman School of Med, Philadelphia, PA
Background/Purpose: Little is known about the incidence of late-onset relapse in systemic vasculitis. This study examined the incidence of relapse < 2 years and ≥ 2…
Abstract Number: 478 • 2016 ACR/ARHP Annual Meeting
Evaluation of the Relationship Between Methotrexate Polyglutamation and Efficacy in the Collagen-Induced Arthritis Mouse Model
Rakesh Singh¹, Leon van Haandel², Paul Kiptoo³, Mara L Becker⁴, Teruna Siahaan³ and Ryan Funk⁵, ¹Department of Pharmacy Practice, University of Kansas Medical Center, Kansas City, KS, ²2401 Gillham Road, Children's Mercy Hospitals and Clinics, Kansas City, MO, ³Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS, ⁴Rheumatology, Children's Mercy Kansas City, Kansas City, MO, ⁵University of Kansas Medical Center, Kansas City, KS
Background/Purpose: Polyglutamate metabolites of methotrexate (MTX) are believed to represent the pharmacologically active form of the drug and have been proposed as a biomarker to…
Abstract Number: 651 • 2016 ACR/ARHP Annual Meeting
Calprotectin Serum Levels Strongly Predict Disease Flare in RA and Psa Patients with Low Disease Activity Treated with TNF Inhibitors. a One-Year Prospective Cohort Study
Jose Inciarte-Mundo¹, M. Victoria Hernández¹, Virginia Ruiz-Esquide¹, Sonia Cabrera-Villalba¹, Julio Ramirez¹, Andrea Cuervo¹, Mariona Pascal², Jordi Yagüe², Juan D. Cañete¹ and Raimon Sanmarti¹, ¹Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ²Immunology Department, Hospital Clinic de Barcelona, Barcelona, Spain
Background/Purpose: An increasing number of RA and PsA patients achieve low levels of disease activity under biological therapy. Thus, new biomarkers are needed to stratify…
Abstract Number: 1050 • 2016 ACR/ARHP Annual Meeting
Defining Low Disease Activity in Systemic Lupus Erythematosus
Ari Polachek¹, Dafna D Gladman², Jiandong Su³ and Murray Urowitz⁴, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Rheumatology, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁴Medicine, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: Remission is a desirable but not a common enough outcome in systemic lupus erythematosus (SLE) and therefore additional measures are needed to evaluate new…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].